Core Viewpoint - The company emphasizes green and low-carbon development in modern agriculture, positioning itself as a leader in the biological pesticide sector, advocating for a green revolution in agriculture [1][2]. Group 1: Company Overview - Shandong Lukang Biological Pesticide Co., Ltd. is a wholly-owned subsidiary of Lukang Pharmaceutical (600789) and is recognized as a national high-tech enterprise and designated pesticide production company [1]. - The company has a comprehensive range of biological pesticides and significant scale advantages, supported by 60 years of technical accumulation in microbial fermentation [1]. Group 2: Product Development and Innovation - The company focuses on discovering natural active ingredients from plant and microbial sources to create biological insecticides, fungicides, and plant growth regulators, contributing to ecological protection in agriculture [1][2]. - Recent investments in research and development have led to breakthroughs in microbial synthesis mechanisms and high-yield engineered strains, enhancing the production of biological pesticides [2]. - Key products include a biocontrol agent for nematodes, which is progressing well in field trials, and several products like multi-fungicides have received U.S. patent authorization, becoming mainstream brands in the market [2]. Group 3: Future Plans and Goals - During the "14th Five-Year Plan" period, the company aims to expand the quantity and scale of fermentation-based pesticides, striving to become a leading biological pesticide enterprise in China [3]. - The company plans to reduce the cost of pesticide formulations and enhance its innovation capabilities, accelerating the registration and production of innovative pesticides to ensure safe agricultural production and ecological balance [3].

每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 （记者 曾健辉） 每经AI快讯，鲁抗医药2月24日晚间发布公告称，近日，山东鲁抗医药股份有限公司控股子公司山东鲁 抗医药集团赛特有限责任公司收到国家药品监督管理局颁发的关于米诺地尔搽剂的《药品注册证书》， 该药品是按照新注册分类3类获批的仿制药，视为通过仿制药质量和疗效一致性评价。产品名称为"米诺 地尔搽剂"。 ...

财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：磐石 格隆汇2月24日丨鲁抗医药(600789.SH)公布，公司控股子公司山东鲁抗医药集团赛特有限责任公司（简 称"赛特公司"）收到国家药品监督管理局颁发的关于米诺地尔搽剂（简称"该药品"）的《药品注册证 书》（批件号：2026S00478、2026S00479），该药品是按照新注册分类3类获批的仿制药，视为通过仿 制药质量和疗效一致性评价。 米诺地尔属于钾通道开放类抗高血压药物但具有多毛症的副作用。美国Upjohn公司针对此种不良反应进 行研究发现其溶液外用治疗秃发有明显疗效。1988年9月经美国FDA批准2%米诺地尔外用溶液上市用于 治疗斑秃男性秃发及化疗后秃发，1991年FDA批准可在妇女中使用，1997年FDA批准上市了5%米诺地 尔外用溶液用于男性患者。目前国内有米诺地尔搽剂、米诺地尔酊等相关剂型用于治疗秃发。本品用于 治疗男性型脱发和斑秃。 ...

智通财经APP讯，鲁抗医药(600789.SH)发布公告，近日，公司控股子公司山东鲁抗医药集团赛特有限 责任公司(以下简称"赛特公司")收到国家药品监督管理局颁发的关于米诺地尔搽剂(以下简称"该药品") 的《药品注册证书》(批件号：2026S00478、2026S00479)，该药品是按照新注册分类3类获批的仿制 药，视为通过仿制药质量和疗效一致性评价。 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2026-008 山东鲁抗医药股份有限公司 关于控股子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，山东鲁抗医药股份有限公司（以下简称"公司"）控股子公司山东鲁 抗医药集团赛特有限责任公司（以下简称"赛特公司"）收到国家药品监督管理 局颁发的关于米诺地尔搽剂（以下简称"该药品"）的《药品注册证书》（批件 号：2026S00478、2026S00479），该药品是按照新注册分类 3 类获批的仿制药， 视为通过仿制药质量和疗效一致性评价。现将相关情况公告如下： 一、药品证书基本信息 药品名称： 米诺地尔搽剂 剂型： 搽剂 规格：5%（60 毫升：3.0 克）、2%（60 毫升：1.2 克） 原药品批准文号：国药准字 H20263408、国药准字 H20263407 药品注册标准编号：YBH35432025 注册分类：化学药品 3 类 生产企业：山东鲁抗医药集团赛特有限责任公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 ...

Investment Rating - The report maintains a "Recommendation" rating for the veterinary medicine industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [80]. Core Insights - In January, the majority of vaccine varieties saw a year-on-year decline in batch approvals, with the Veterinary Product Index (VPI) dropping 1.8% month-on-month, marking three consecutive months of decline [2][3]. - The report highlights that the overall performance of the animal vaccine and veterinary medicine sector has been affected by high base effects from the previous year, low breeding sentiment, and the timing of the Spring Festival impacting stocking rhythms [10][57]. - The report emphasizes the importance of innovation in driving performance, noting that companies demonstrating product, marketing, or capital operation innovations have shown better financial results [71][72]. Summary by Sections Vaccine Batch Approvals - In January, most vaccine products experienced a year-on-year decline in batch approvals. For pig vaccines, the majority saw declines, with only pseudorabies and blue ear vaccines showing increases of 13.1% and 30.2%, respectively. Other vaccines like foot-and-mouth disease and porcine circovirus vaccines saw declines ranging from 20% to 50% [9][10]. - In the poultry vaccine segment, the H5N1 trivalent vaccine and Marek's vaccine saw declines of 13.8% and 25.9%, respectively, while the newcastle disease vaccine remained flat [9][10]. Veterinary Raw Materials - The VPI index averaged 66.16 in January, down 1.8% from December, with a continued downward trend observed in the prices of most raw materials. For instance, the price of florfenicol dropped by 4.5% month-on-month, while amoxicillin saw a slight increase of 0.7% [57][58]. - Year-on-year comparisons show that while some products like tylosin and tilmicosin have seen significant price increases, amoxicillin has dropped by 28.8% [58][57]. Investment Recommendations - The report suggests focusing on undervalued companies with improvement logic, highlighting that the ongoing industry competition has led to a market environment where only innovative companies are likely to thrive. Recommended companies include Zhongmu Co., Ltd., Reap Bio, and others [71][73].

Core Viewpoint - The recent 60 billion yuan private placement plan by Southwest Securities marks a significant event in the brokerage industry, indicating a revival in the refinancing market following new policies introduced by the Shanghai and Shenzhen Stock Exchanges [2][5]. Group 1: Market Trends - The brokerage refinancing market has shifted from a low point to recovery, with several firms successfully completing private placements in 2025, including Guolian Minsheng Securities (2 billion), Guotai Junan Securities (10 billion), and others totaling 60 billion yuan [2][4]. - The total amount raised through private placements by brokerages in 2025 reached 716.89 billion yuan, a fivefold increase compared to 2024 [10]. Group 2: Capital Utilization - The funds raised through private placements are increasingly being allocated to a balanced development strategy rather than solely focusing on proprietary trading, with Southwest Securities planning to invest in securities investment and debt repayment, each not exceeding 15 billion yuan [7][8]. - Other brokerages, such as Tianfeng Securities and Nanjing Securities, have also shown a trend towards diversifying their capital allocation, focusing on wealth management, technology, and compliance [8][9]. Group 3: Strategic Support - The involvement of controlling shareholders in underwriting and committing to long-term holdings has become a common practice, as seen with Southwest Securities and other firms, which enhances market confidence [5][6]. - The regulatory environment has shifted towards differentiated easing, encouraging brokerages to enhance their operational quality and efficiency rather than merely expanding in scale [12].

Overview - The company, Shandong Lukang Pharmaceutical Co., Ltd., has approved the government acquisition of part of its state-owned land use rights, involving a total area of 237,100 square meters (approximately 355.65 acres) [1] - The company will receive a total compensation of 360.396 million yuan for the land acquisition, which includes a specific compensation of 22.82256 million yuan for land previously owned by Shandong Lukang Pharmaceutical Group Co., Ltd. [1] Compensation Progress - The company has received a total of 152.277 million yuan in land compensation payments to date, with an outstanding balance of 208.119 million yuan yet to be received [2] - The compensation payments were received in multiple installments, including 20 million yuan on September 29, 2024, 32.277 million yuan on May 22, 2025, 50 million yuan on August 27, 2025, 20 million yuan on September 25, 2025, and 10 million yuan on December 30, 2025 [2] Future Actions - The company will closely monitor and follow up on the progress of the remaining land compensation payments and related matters, ensuring timely information disclosure to investors [3]

证券代码:600789 证券简称:鲁抗医药 公告编号:2026-007 山东鲁抗医药股份有限公司 （公告编号：2022-066）、《鲁抗医药关于公司南厂区土地办理完成移交手续 暨进展公告》（公告编号：2024-034）。 2024年9月29日，公司收到第一笔土地收储补偿款2,000万元；2025年5月22 日，公司收到第二笔土地补偿款3,227.70万元；2025年8月27日，公司收到第三 笔土地补偿款5,000万元；2025年9月25日，公司收到第四笔土地补偿款2,000万 元；2025年12月30日，公司收到第五笔土地补偿款1,000万元。具体内容详见公 司2024年9月30日、2025年5月23日、2025年8月28日、2025年9月26日、2025年 12月31日披露的《关于收到南厂区土地收储补偿款的进展公告》（公告编号： 2024-048、2025-025、2025-042、2025-049、2025-060）。 二、本次收储相关事项的进展情况 2026年2月13日，公司收到第六笔土地补偿款2,000万元。截至目前公司已 收到土地补偿款15,227.70万元，尚未收到补偿款余额20,811.90万元 ...

Group 1 - The company announced the acquisition of five state-owned construction land parcels totaling 237,100 square meters, with a total compensation fee of 360.396 million yuan [1] - As of February 13, 2026, the company received the sixth installment of land compensation amounting to 20 million yuan [1] - The total compensation received to date is 152.277 million yuan, with an outstanding balance of 208.119 million yuan yet to be received [1]